Male Hypogonadism - Pipeline Review, H1 2015

Published: Jan, 2015 | Pages: 100 | Publisher: Global Markets Direct
Industry: Pharmaceuticals & Healthcare | Report Format: Electronic (PDF)

Male Hypogonadism - Pipeline Review, H1 2015

Summary

Global Markets Direct's, 'Male Hypogonadism - Pipeline Review, H1 2015', provides an overview of the Male Hypogonadism's therapeutic pipeline.

This report provides comprehensive information on the therapeutic development for Male Hypogonadism, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Male Hypogonadism and special features on late-stage and discontinued projects.

Global Markets Direct's report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct's proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct's team. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis.

The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Scope

- The report provides a snapshot of the global therapeutic landscape of Male Hypogonadism
- The report reviews key pipeline products under drug profile section which includes, product description, MoA and R&D brief, licensing and collaboration details & other developmental activities 
- The report reviews key players involved in the therapeutics development for Male Hypogonadism and enlists all their major and minor projects
- The report summarizes all the dormant and discontinued pipeline projects 
- A review of the Male Hypogonadism products under development by companies and universities/research institutes based on information derived from company and industry-specific sources
- Pipeline products coverage based on various stages of development ranging from pre-registration till discovery and undisclosed stages
- A detailed assessment of monotherapy and combination therapy pipeline projects
- Coverage of the Male Hypogonadism pipeline on the basis of target, MoA, route of administration and molecule type
- Latest news and deals relating related to pipeline products

Reasons to buy

- Provides strategically significant competitor information, analysis, and insights to formulate effective R&D development strategies
- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
- Develop strategic initiatives by understanding the focus areas of leading companies
- Identify and understand important and diverse types of therapeutics under development for Male Hypogonadism
- Plan mergers and acquisitions effectively by identifying key players of the most promising pipeline
- Devise corrective measures for pipeline projects by understanding Male Hypogonadism pipeline depth and focus of Indication therapeutics
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
- Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline

 Table of Contents
Table of Contents 2
List of Tables 6
List of Figures 7
Introduction 8
Global Markets Direct Report Coverage 8
Male Hypogonadism Overview 9
Therapeutics Development 10
Pipeline Products for Male Hypogonadism - Overview 10
Pipeline Products for Male Hypogonadism - Comparative Analysis 11
Male Hypogonadism - Therapeutics under Development by Companies 12
Male Hypogonadism - Therapeutics under Investigation by Universities/Institutes 14
Male Hypogonadism - Pipeline Products Glance 15
Late Stage Products 15
Clinical Stage Products 16
Early Stage Products 17
Male Hypogonadism - Products under Development by Companies 18
Male Hypogonadism - Products under Investigation by Universities/Institutes 20
Male Hypogonadism - Companies Involved in Therapeutics Development 21
AlphaMab Co., Ltd 21
Antares Pharma, Inc. 22
Auxilium Pharmaceuticals, Inc. 23
Clarus Therapeutics, Inc. 24
Diurnal Ltd 25
EndoCeutics, Inc. 26
Ferring International Center S.A. 27
Forendo Pharma Oy 28
Lipocine Inc. 29
M et P Pharma AG 30
Merck & Co., Inc. 31
Monosol Rx, LLC 32
Novartis AG 33
Pantarhei Bioscience BV 34
Repros Therapeutics Inc. 35
SoluBest Ltd. 36
Male Hypogonadism - Therapeutics Assessment 37
Assessment by Monotherapy Products 37
Assessment by Target 38
Assessment by Mechanism of Action 40
Assessment by Route of Administration 42
Assessment by Molecule Type 44
Drug Profiles 46
BGS-649 - Drug Profile 46
Product Description 46
Mechanism of Action 46
R&D Progress 46
corifollitropin alfa - Drug Profile 47
Product Description 47
Mechanism of Action 47
R&D Progress 47
enclomiphene - Drug Profile 49
Product Description 49
Mechanism of Action 49
R&D Progress 49
fispemifene - Drug Profile 51
Product Description 51
Mechanism of Action 51
R&D Progress 51
follitropin alfa - Drug Profile 53
Product Description 53
Mechanism of Action 53
R&D Progress 53
Kisspeptin-10 - Drug Profile 54
Product Description 54
Mechanism of Action 54
R&D Progress 54
Libidua - Drug Profile 55
Product Description 55
Mechanism of Action 55
R&D Progress 55
LPCN-1111 - Drug Profile 56
Product Description 56
Mechanism of Action 56
R&D Progress 56
T-2 - Drug Profile 57
Product Description 57
Mechanism of Action 57
R&D Progress 57
Testavan - Drug Profile 58
Product Description 58
Mechanism of Action 58
R&D Progress 58
testosterone - Drug Profile 59
Product Description 59
Mechanism of Action 59
R&D Progress 59
testosterone - Drug Profile 60
Product Description 60
Mechanism of Action 60
R&D Progress 60
testosterone - Drug Profile 62
Product Description 62
Mechanism of Action 62
R&D Progress 62
testosterone - Drug Profile 63
Product Description 63
Mechanism of Action 63
R&D Progress 63
testosterone - Drug Profile 64
Product Description 64
Mechanism of Action 64
R&D Progress 64
testosterone - Drug Profile 65
Product Description 65
Mechanism of Action 65
R&D Progress 65
testosterone - Drug Profile 66
Product Description 66
Mechanism of Action 66
R&D Progress 66
testosterone enanthate - Drug Profile 68
Product Description 68
Mechanism of Action 68
R&D Progress 68
testosterone next generation - Drug Profile 69
Product Description 69
Mechanism of Action 69
R&D Progress 69
testosterone undecanoate - Drug Profile 70
Product Description 70
Mechanism of Action 70
R&D Progress 70
testosterone undecanoate - Drug Profile 72
Product Description 72
Mechanism of Action 72
R&D Progress 72
testosterone undecanoate - Drug Profile 73
Product Description 73
Mechanism of Action 73
R&D Progress 73
Male Hypogonadism - Recent Pipeline Updates 74
Male Hypogonadism - Dormant Projects 90
Male Hypogonadism - Discontinued Products 91
Male Hypogonadism - Product Development Milestones 92
Featured News & Press Releases 92
Jan 13, 2015: Antares Pharma Announces Update To Quickshot Testosterone Program 92
Dec 29, 2014: Court Rules Inventors Correctly Named on Androxal Patents 92
Dec 29, 2014: Repros Updates Androxal Global Regulatory Status 93
Dec 16, 2014: SOV Therapeutics announces Successful Phase IIb Study of Oral Testosterone Undecanoate for Treatment of Primary and Secondary Hypogonadism in Adult Males 94
Dec 16, 2014: SOV Therapeutics announces Successful Phase IIb Study of Oral Testosterone Undecanoate for Treatment of Primary and Secondary Hypogonadism in Adult Males 94
Dec 15, 2014: FDA Confirms Lipocine's Previously-Agreed Clinical Development Plan for LPCN 1021 95
Nov 25, 2014: Trimel Announces Issuance of Additional Patent Covering NATESTO 95
Nov 03, 2014: Antares Pharma Announces Last Patient Enrolled in Phase 3 QuickShot Study Evaluating Testosterone-Deficient Adult Males 96
Oct 27, 2014: Repros to Webcast Investor and Analyst Day on October 31st 96
Oct 21, 2014: Results From Long-Term Study of Androxal Exhibit Positive Safety Profile 97
Appendix 99
Methodology 99
Coverage 99
Secondary Research 99
Primary Research 99
Expert Panel Validation 99
Contact Us 99
Disclaimer 100

List of Tables
Number of Products under Development for Male Hypogonadism, H1 2015 10
Number of Products under Development for Male Hypogonadism - Comparative Analysis, H1 2015 11
Number of Products under Development by Companies, H1 2015 13
Number of Products under Investigation by Universities/Institutes, H1 2015 14
Comparative Analysis by Late Stage Development, H1 2015 15
Comparative Analysis by Clinical Stage Development, H1 2015 16
Comparative Analysis by Early Stage Development, H1 2015 17
Products under Development by Companies, H1 2015 18
Products under Development by Companies, H1 2015 (Contd..1) 19
Products under Investigation by Universities/Institutes, H1 2015 20
Male Hypogonadism - Pipeline by AlphaMab Co., Ltd, H1 2015 21
Male Hypogonadism - Pipeline by Antares Pharma, Inc., H1 2015 22
Male Hypogonadism - Pipeline by Auxilium Pharmaceuticals, Inc., H1 2015 23
Male Hypogonadism - Pipeline by Clarus Therapeutics, Inc., H1 2015 24
Male Hypogonadism - Pipeline by Diurnal Ltd, H1 2015 25
Male Hypogonadism - Pipeline by EndoCeutics, Inc., H1 2015 26
Male Hypogonadism - Pipeline by Ferring International Center S.A., H1 2015 27
Male Hypogonadism - Pipeline by Forendo Pharma Oy, H1 2015 28
Male Hypogonadism - Pipeline by Lipocine Inc., H1 2015 29
Male Hypogonadism - Pipeline by M et P Pharma AG, H1 2015 30
Male Hypogonadism - Pipeline by Merck & Co., Inc., H1 2015 31
Male Hypogonadism - Pipeline by Monosol Rx, LLC, H1 2015 32
Male Hypogonadism - Pipeline by Novartis AG, H1 2015 33
Male Hypogonadism - Pipeline by Pantarhei Bioscience BV, H1 2015 34
Male Hypogonadism - Pipeline by Repros Therapeutics Inc., H1 2015 35
Male Hypogonadism - Pipeline by SoluBest Ltd., H1 2015 36
Assessment by Monotherapy Products, H1 2015 37
Number of Products by Stage and Target, H1 2015 39
Number of Products by Stage and Mechanism of Action, H1 2015 41
Number of Products by Stage and Route of Administration, H1 2015 43
Number of Products by Stage and Molecule Type, H1 2015 45
Male Hypogonadism Therapeutics - Recent Pipeline Updates, H1 2015 74
Male Hypogonadism - Dormant Projects, H1 2015 90
Male Hypogonadism - Discontinued Products, H1 2015 91